Natasha Tiffany, MD, an experienced oncologist based in Salem, Oregon, treats cancer patients at Oregon Oncology Specialists, where she is a physician partner, and at Salem Hospital. She also teaches as an affiliate assistant professor with Oregon Health & Science University in Portland. At Oregon Oncology Specialists, Natasha Tiffany, MD, and the practice’s team of doctors utilize state of the art cancer care strategies, including immunotherapy. Immunotherapy harnesses the power of a patient’s immune system to attack and destroy cancer cells. This category of cancer-fighting treatment encompasses many distinct approaches. For example, some immunotherapies rely on genetically modified viruses that eliminate malignant cells, while another relies on a patient’s T-cells. The year 2018 was a significant time for immunotherapy advancements. For instance, several immunotherapy drugs secured Food and Drug Administration (FDA) approval. The regulatory body approved Pembrolizumab, a medication that prevents tumors from utilizing part of the immune system to their own benefit, to treat people living with advanced cervical cancer. Other immunotherapy drugs approved by the FDA include Durvalumab and Nivolumab. In addition to drug approvals, immunotherapy research continues to show promise. In one example, researchers are actively exploring vaccines to boost the immune response against such cancers as glioblastoma and melanoma.
0 Comments
Leave a Reply. |
AuthorNatasha Tiffany, MD, is a physician, educator, and research scientist currently working in Oregon. A Partner and Physician in a private practice located in the state’s capital city of Salem, Dr. Tiffany teaches at her alma mater, Oregon Health & Science University, where she is an Affiliate Assistant Professor in the Hematology and Medical Oncology Division. Archives
October 2019
Categories
All
|